European approval for 'Dovato', ViiV's dual regimen for HIV
The European Commission has approved the marketing authorization for the dolutegravir/lamivudine combination for the treatment of HIV-1 infection in adults and adolescents aged 12 years and over. Editorial Staff, July 8, 2019. ViiV Healthcare announces that the European Commission has granted marketing authorization to Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection […]
European approval for 'Dovato', the double ViiV regimen for HIV Read More »










